A
Alcista
Alcista · 25%CTKB
$3.14
Precio del escenario
$5.250
-0.155 (-2.96%)Al cierre
Loading chart…
- Máximo
- 5.410
- Apertura
- 5.410
- Precio medio ponderado por volumen
- 5.29
- Volumen
- 1.05M
- Capitalización
- 720.69M
- Mínimo
- 5.205
- Importe
- 5.53M
- EV/EBITDA, TTM
- -12.16
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Análisis de IA of Cytek Biosciences Inc (CTKB)
ComprarCytek Biosciences Inc (CTKB) is a good buy right now due to its current price of $5.43 being below the analyst target price of $5.56, indicating potential upside. Additionally, the stock has shown a strong 1-year change of +37.12%, reflecting positive long-term growth. However, the forward P/E ratio is extremely high at 370.37, indicating potential overvaluation risk.
Métricas de valoración
El PER previsto actual de Cytek Biosciences Inc (CTKB) es 370.37, frente a su media de 5 años de 121.02.
Escenarios de precio de Alphio AI para CTKB
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CTKB en cartera
Cronología de eventos
Noticias
6.009-23NASDAQ.COMCytek BioSciences Stock Surpasses Analyst Target Price
7.509-09NewsfilterSysmex and Cytek Announce Strategic Collaboration
- 8.509-03Newsfilter
Cytek Biosciences to Showcase Advanced Technology at Clinical Cytometry Events
- 7.008-21Newsfilter
Cytek Biosciences Wins Patent Infringement Case
4.507-16NASDAQ.COMCytek Biosciences Opens Innovation Center in Washington
Preguntas frecuentes sobre CTKB, respondidas por Alphio AI
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Cytek Biosciences Inc (CTKB) is a good buy right now due to its current price of $5.43 being below the analyst target price of $5.56, indicating potential upside. Additionally, the stock has shown a strong 1-year change of +37.12%, reflecting positive long-term growth. However, the forward P/E ratio is extremely high at 370.37, indicating potential overvaluation risk.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.